Table 2.
Bivariate analysis of factors associated with an outcome of HIV-1 RNA <50 copies/mL at week 48 of antiretroviral treatment
| Risk factor | Bivariate | P value | |
|---|---|---|---|
| OR unadjusted | 95% CI | ||
| Male sex | 1.02 | 0.29–3.52 | 0.967 |
| Age >40 years | 2.09 | 0.77–5.81 | 0.150 |
| Number of previous regimens >6 | 0.839 | 0.28–2.44 | 0.746 |
| Baseline HIV‐1 RNA >100,000 copies/mL | 0.47 | 0.17–1.32 | 0.150 |
| Baseline CD4+ cell count <200 cells/μL | 0.44 | 0.18–1.00 | 0.050 |
| GSS ≥2 | 1.22 | 0.48-3.10 | 0.674 |
| TDF | 0.64 | 0.26–1.60 | 0.34 |
| ETV | 1.15 | 0.43–3.10 | 0.77 |
| EFV | 1.11 | 1.03–1.20 | 0.073 |
| MVC | 1.11 | 1.03–1.20 | 0.073 |
| ENF | 0.37 | 0.11–1.23 | 0.09 |
CI confidence interval, EFV efavirenz, ENF enfuvirtide, ETV etravirine, GSS genotypic sensitivity score, MVC maraviroc, OR odds ratio, TDF tenofovir